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Précis: Combination of treatments is the most effective option for vulvodynia patients 
in terms of pain reduction. 
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Abstract 
 
Objectives: 8 % of women suffer from vulvodynia (VD), a chronic pain disorder with 
unknown etiology. Aims of our study were to assess the efficacy of given VD 
treatments measured by numerical self-reported pain score (NRS) and patients’ 
quality of life. 
 
Methods: Study material consisted of a retrospective VD patient cohort (n=70). Data 
was collected by postal questionnaires and review of the medical records. 
 
Results: We report here a statistically significant reduction in NRS only with 
combination of therapies (median NRS before treatments 8 vs. median NRS 4 after 
treatments, p<0.001) but not with any individual therapy alone i.e. physiotherapy, 
topical medications, oral pharmaceutical therapy, sexual counseling by a trained 
nurse, sacral neuromodulation, laser treatment or surgery. Older age (>30) and 
frequent (≥6) outpatient clinic visits associated with a significantly minor reduction in 
NRS (p=0.03 and p=0.04, respectively). 
 
Conclusions: The results of this retrospective study suggest, that an effective, 
multimodality-based treatment is most beneficial for VD patients, and VD at older 
age may represent a subtype more resistant to therapy. 
 
Key words: Vulvodynia, treatment, combination therapy, older age, quality of life, 
outpatient clinic, retrospective cohort 
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Introduction 
 
Vulvodynia (VD) is a condition characterized by chronic pain, the etiology of which 
remains largely unknown. It is quite common, affecting 8% of women 1 yet highly 
under diagnosed. The 2015 Consensus Terminology and Classification of Persistent 
Vulvar pain and Vulvodynia defines VD as vulvar pain of at least 3 months’ duration, 
without clear identifiable cause, which may have potential associated factors 2.VD-
related pain can be described by the localization of the pain (localized, generalized or 
mixed), type of the pain (provoked, spontaneous or mixed), onset of pain (primary, 
secondary) and by its temporal pattern (intermittent, persistent, constant, immediate, 
delayed) 2. Pathomechanisms of VD are still unclear but recent studies imply that 
inflammation may play a role in localized provoked VD 3.  One typical clinical 
finding preceding VD is occurrence of recurrent yeast infections. Also, genetic 4 
and hormonal factors may associate with the onset of VD, yet a study concerning risk 
of VD among oral contraceptive users showed that the association is not clear 5. 
Neuropathic pain 6 and pelvic floor muscle dysfunction may play a role 7. VD is 
believed to be multifactorial and different subcategories may have different etiologies. 
Multifactorial pathomechanisms may also explain why superior treatment is still 
elusive. In practice, many different treatment modalities are used, without good 
quality evidence of their efficiency. 
 
Limited number of randomized placebo-controlled studies has been published. To our 
knowledge, only physiotherapy (TENS) 8 and enoxaparin-injections 9 have 
proven their efficacy in a controlled randomized setting in treatment of VD patients. 
Published controlled studies indicate also good responses to placebo 10,11,12. Most 
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of the VD treatment protocols use a combination of therapies tailored to an individual 
patient’s needs. VD treatment protocols rely largely on expert opinions or on 
empirically based treatments. 
 
VD causes significant burden to healthcare system, patient and her intimate partner. 
Recent study showed that VD caused over 8,800 dollars of direct and indirect 
healthcare costs 13 per one individual patient over a six-month period. High 
treatment costs highlight the need to evaluate the efficiency of treatments and 
treatment protocols as well as the patients’ experience with these processes. 
 
The aim of this study was to retrospectively characterize our center’s VD patient 
cohort. Our aim was to obtain data on the efficacy of given treatments, as measured 
by self-reported numerical pain score (NRS) and on demographic and other factors 
influencing the treatment outcome. Finally, the quality of life experienced by VD 
patients was assessed before and after treatments. 
 
Methods 
 
This retrospective cohort study was carried out at Tampere University Hospital 
(TAUH), Tampere, Finland. The study protocol was approved by TAUH Ethical 
Committee. The study included women over 18 years of age and diagnosed with VD 
at TAUH during years 2003-2013. The diagnoses are based on the International 
Classification of Diseases (ICD) and during our study period, ICD-10 has been used 
in Finland [14]. To identify VD patients, we used following ICD-codes as a searching 
criteria from the electronic patient record: N94.1 Dyspareunia, N94.2 Vaginismus, 
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N90.8 Other specified noninflammatory diseases of vulva and perineum, N90.9 
Noninflammatory disease of vulva and perineum, unspecified . Three authors (AA, 
SV, HT) read through the patient record. All VD patients included in our study had to 
fulfill the Friedrich’s two criteria [15] (pain on attempted vaginal entry and tenderness 
to pressure localized within the vulvar vestibule) and pain symptoms lasting minimum 
three months. Patients diagnosed with candidiasis or other infection were properly 
treated and if their symptoms resolved after antifungal or antibacterial treatment, they 
were excluded from our study. Due to the retrospective study period of 2003-2013, 
the previous “2003 ISSVD Terminology and Classification of Vulvar pain” 16  was 
used as a basis of categorization (local vs. generalized) of VD. From hospital registry, 
a total of 133 patients met the diagnostic criteria of VD, including severe pain on 
vestibular touch or attempted vaginal entry and tenderness to localized pressure 
within the vulvar vestibule. Patients with vulvar malignancy, and other ongoing 
inflammatory or skin diseases of vulva were excluded. All patients participating in the 
study were provided with an informed consent. The design of the study is shown in 
Figure 1. 
 
Clinical data and patients’ demographic factors were collected from the patient 
records. Clinical data included patient’s medical history, past or current psychiatric 
disorder (depression or bipolar disorder), regular medication, type of VD (local vs. 
generalized), various VD treatment modalities and number of outpatient visits. 
Various treatment modalities follow a certain protocol in our University hospital. This 
protocol has been in clinical use since 2009, presented in detail in Figure 2. 
Participants of the study were also asked to complete a postal questionnaire 
addressing vulvar pain intensity on the numeric rating scale (NRS) before and after 
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treatment, quality of life and treatment satisfaction. NRS was used to quantify the 
intensity of vulvar pain by rating the pain using a 0-to-10 scale, where 0 was “no 
pain” and 10 was “the worst pain imaginable”. Questionnaires were re-sent to patients 
who did not return questionnaires in 1.5 months from the first mailing. Detailed 
description of the questionnaire is presented in Table 1. 
 
Version 23 of IBM SPSS statistics software was used in statistical analyses (IBM 
SPSS Statistics for Windows, Version 23.0. IBM Corp. 2015. Armonk, NY, USA).  
Mann Whitney U-test was used to compare patient-reported NRS values after 
different treatment modalities. Wilcoxon signed rank-test was used to study the 
overall effect of combination of treatments on NRS values. The associations between 
number of outpatient clinic visits, patient age, presence of co-morbidities, quality of 
life and patient-reported NRS values was also analyzed by Mann-Whitney U-test. The 
difference in patient-reported scores describing satisfaction with treatments given by 
different professionals (i.e. physicians, physiotherapists, trained nurses) was analyzed 
using Wilcoxon signed rank-test. An alpha level of 0.05 was used for all statistical 
tests. 
 
Results 
 
Seventy (52.6 %) patients returned the questionnaire. Characteristics of the study 
population are shown in Table 2. The most common conservative treatment 
modalities used included locally administered desensitizing gel (82.9%), 
physiotherapy (78.6%) and sexual counseling by a trained nurse (74.3%). Various 
treatment combinations given are summarized in Table 3. 
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Median NRS value representing vulvar pain intensity before treatment was 8.0 (IQR 
8-9) and at the end of treatment 4.0 (IQR 2-7). The overall effect of all treatments was 
associated with a statistically significant reduction in NRS values before and after 
treatments (p<0.001, Wilcoxon signed rank-test, Table 4a). When the NRS score after 
individual treatments between groups (treatment/no treatment) was compared, no 
statistically significant differences were found (Table 4b). Type of VD (local vs. 
generalized) did not associate with treatment outcome (median reduction in NRS 4 
(IQR 2-6) vs. 3 (IQR 1-7) for patients with local pain vs. generalized pain syndrome, 
p=0.76; Mann-Whitney U-test). 
 
The median age of patients was 30 years (IQR 25-41). When age was categorized 
using the median value as cut-off point, reduction in NRS score was significantly 
lower after treatment for older patients (median reduction in NRS 2, IQR 1-6 vs. 5 
IQR 2-7, p=0.032; Mann-Whitney U-test). Median number of outpatient clinic visits 
was four (range 1-17, IQR 2-6). Greater number (≥6) of outpatient clinic visits 
associated with significantly minor reduction in NRS (median reduction in NRS 2, 
IQR 1-5 vs. 4, IQR 2-7; p=0.043, Mann-Whitney U-test).  However, age was not 
associated with the number of outpatient clinic visits (median number of visits 4 
among both patients 30 and >30 years of age, respectively, p=0.79, Mann-Whitney 
U-test). The median time interval from onset of VD symptoms to initiation of therapy 
was 1 year (IQR 0.5-4.75), which did not associate significantly with the treatment 
outcome (median reduction in NRS 4 IQR 2-7 vs. 3 IQR 1-7 for patients with <1 year 
from onset of symptoms vs. ≥1 year, respectively, p=0.35, Mann-Whitney U-test). 
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A history of psychiatric disorder (depression or bipolar disorder) did not associate 
statistically significantly with poorer outcome when comparing VD patients with or 
without psychiatric disorder (median reduction in NRS 2 vs. 4, p=0.27; median 
pretreatment NRS 9, IQR 8-9 vs. 8, IQR 8-9 for patients with psychiatric vs. no 
psychiatric disorder, p=0.27; and median post-treatment NRS 6.5, IQR 2.3-8 vs. 4, 
IQR 2-6.5 for patients with psychiatric vs. no psychiatric disorder, p= 0.07; Mann-
Whitney U-test). 
 
In evaluation of patients’ experiences with treatments given by different 
professionals, scores 4 and 5 were considered satisfactory. Patient satisfaction with 
different professionals was high: 77.1% of patients was satisfied with treatment given 
by physiotherapists while the corresponding numbers were 65.7% for physicians and 
51.5 % for trained nurses (sexual counseling). The patient-reported median score for 
physiotherapists was 5 (IQR 4-5). Median score for physicians was 4 (IQR 4-5) and 
sexual counseling by a trained nurses median score was 4 (IQR 3-5). The patients 
were significantly more satisfied with treatment given by physiotherapists than 
physicians (p=0.015, Wilcoxon signed rank test). Satisfaction with physiotherapists 
was also significantly higher when compared to trained nurses (p<0.001, Wilcoxon 
signed rank test). Satisfaction towards physicians and trained nurses didn’t have 
statistically significant difference (p=0.17 Wilcoxon signed rank test). Patients 
satisfied with treatment given by doctors reported more pronounced reduction in NRS 
(median reduction in NRS 4 IQR 2-7 vs. reduction in NRS 2 IQR 1-5.25), but the 
change was not statistically significant (p=0.053, Mann-Whitney U-test) compared to 
not satisfied patients. 
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Most patients (67.1%) reported good quality of life at survey. Using a 0-to-5 scale, 
quality of life was considered good if patient reported scores 4 (“satisfied”) or 5 
(“very satisfied”). Self-reported pre-treatment NRS values did not affect the quality of 
life (median NRS 9 IQR 8-9 vs. 8 IQR 8-9 for patients reporting good quality of life 
vs. not good quality of life; p=0.327). Patients reporting good quality of life reported 
also lower NRS score after treatment (median reduction in NRS 6 IQR 3-7 vs. 1 IQR 
0-2, p<0.001; and median NRS after treatment 3 IQR 2-5 vs. 7 IQR 6-8, p<0.001 for 
patients reporting good quality of life compared to patients who did not report good 
quality of life, respectively; Mann-Whitney U-test). 
 
Discussion 
 
We describe here characteristics of a retrospective VD patient cohort from a 
University hospital setting. This study suggests that a combination of treatments given 
by a multidisciplinary team reduces the pain of VD patients significantly. Even 
though there was insufficient evidence to support the efficiency of individual 
treatments, this study suggests that VD patients seem to benefit from a combination of 
treatments, which lead to reduction of experienced pain nearly to half of original. 
Individualized treatments for VD are generally considered the best option based on 
the Vulvodynia guideline [17] and multidisciplinary approach is recommended based 
on a systematic review [18]. The results of our study are in line with  previous data 
concerning multimodal treatments.  
 
Data from this study suggests that increasing the number of outpatient clinic visits 
may not be beneficial in terms of reduction in VD-associated pain. Treatment costs 
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grow by every visit, yet fail to reduce the self-reported pain and therefore may be 
cost-ineffective.  For an individual VD patient, estimated cost of office visits was 
2233.62 dollar per 6 months in one study 13.  To our knowledge, this was the first 
attempt to evaluate the impact of several office visits on treatment outcome of VD. 
Another way of interpreting the result is that there’s a population among VD patients 
resistant to given treatment modalities. 
 
Another finding in our study was that age (>30 years) associated with less reduction 
in after-treatment NRS score. This may suggest that older VD patients represent a VD 
subgroup more resistant to treatments. Yet, the type of VD (localized vs essential) did 
not have a statistically significant impact on treatment outcome nor did the time 
interval between the onset of symptoms and VD diagnosis. Therefore, our results 
suggest that age may represent an independent prognostic factor for VD treatment 
failure. Reed et al 19 found four different VD subgroups based on a cluster analysis 
(provoked vs. spontaneous and with or without other comorbid pain conditions) that 
did not differ in age but in general health measures, psychiatric conditions and vulvar 
pain characteristics. In line with our results with respect to patients’ age, Coady et al 
20 recently reported that women younger than 30 years had a better VD outcome 
after arthroscopy for femoro-acetabular impingement. It is of great importance to 
identify different subgroups in VD patients when pathophysiology of VD in general 
remains unclear. Older VD patients could be evaluated as a separate VD subgroup to 
identify the underlying pathophysiological mechanisms and more efficient treatment. 
 
Women with co-existing current major depressive disorder and VD experience more 
severe pain and worse quality of life than VD patients with no comorbid psychiatric 
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disease 21. According to recent study, VD patients with spontaneous pain and other 
comorbidities have highest morbidity in psychiatric disorders 19.Women with 
significant psychiatric distress are less likely to respond to VD treatments 21,22. 
However, in our study, we did not find a statistically significant association between 
psychiatric disorder and poorer treatment outcome. That can be due to small sample 
size or the fact that our patients did not necessarily suffer from psychiatric disorder at 
the time of VD treatments. 
 
Here, we report that quality of life after multimodal treatments was significantly 
better for those VD patients who reported lower post-treatment NRS-values. In a 
previous study [13] vulvodynia patients reported lower quality of life than kidney 
transplant recipients or people with prior osteoporosis-related fracture. In another 
study, chronic pelvic pain was associated with worse quality of life, independent of 
the causal factor [23]. Considering these results, we suggest that reducing vulvodynia 
related pain is the best approach to improve patients’ quality of life. 
 
During the study period and when the retrospective patient cohort was treated for their 
pain symptoms, the terminology and classification of VD in clinical use was the prior 
one “2003 ISSVD Terminology and Classification of Vulvar pain” 16. In our study, 
vulvodynia was subcategorized as “localized” or “generalized”, which is based on the 
old terminology in use during the study period. The new, “2015 consensus 
terminology and classification of persistent vulvar pain and vulvodynia” [2] has more 
pain descriptors (i.e. onset, temporal pattern) and our study subcategorizes VD pain 
only by its location. This is a confounding factor when interpreting our results. 
However, the authors state that the original patient sample would have been the same 
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(Friedrich’s criteria for inclusion) but analyses of subcategories may have led in 
different results if we had used the new, 2015 consensus terminology as a basis in 
categorization. Our decision to include patients that fulfilled the Friedrich’s first two 
criteria minimize the possibility that some real VD patients would have been ruled out 
from the study because the change in classification.  
 
This study has certain limitations. The study cohort was relatively small and response 
rate to the questionnaire was somewhat low (52.6%) possibly causing biases such as 
selection and information bias. It is possible that non-responding patients may have 
been unsatisfied with their treatment and would have reported higher NRS-numbers 
than patients attending to this study. Non-responders may also represent a patient 
cohort with e.g. more psychiatric co-morbidity and therefore less active behavior and 
this should be considered when interpreting the results. None of the individual 
therapies seemed to be efficient alone, but small sample size in subgroups may have 
caused lack of power in statistical analysis. Pain was assessed retrospectively by self-
reported questionnaires. Long time span between treatments and assessment of pain 
may have had an effect on self-reported pain. Maximum time span between 
treatments and self-assessment was 11 years and minimum one year. However, self-
reported pain has been shown to have a good reliability and validity when predicting 
VD previously 24. Before establishment of the specific “Vulva clinic” in 2009, the 
diagnostic accuracy and documentation of VD symptoms may have varied. It is 
possible that some of the original VD patients have not been documented in a proper 
way in the hospital records, and that may have reduced the retrospective patient 
sample size. The treatment protocol for VD patients has been in use since 2009. It is 
possible that VD patients treated before 2009 have not had the possibility to get 
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physiotherapy or sexual counseling routinely which may be a confounding factor 
when interpreting results. Also, the decision to include only patients whose symptoms 
fulfilled the Friedrich’s two criteria (pain on attempted vaginal entry and tenderness 
to pressure localized within the vulvar vestibule) 15 and who were documented in 
the patient records, may have excluded some true VD patients who lacked the verbal 
description of the symptoms in their records. The possibility that patients with 
recurrent candidiasis or some other vaginal infection only would have been diagnosed 
as VD patients is ruled out because the patients had to fulfill the Friedrich’s two first 
criteria even after the proper treatment of yeast or bacterial infection to be included in 
this study. However, despite these limitations, we feel that our study does contribute 
to the knowledge on VD, as the sample size of 70 patients favors well with previously 
published studies. 
 
In conclusion, our study suggests that combination of treatments is the most beneficial 
option for VD patients in terms of pain reduction and has a positive effect on quality 
of life. Older age may represent a subtype in VD more resistant to treatment 
warranting further prospective studies. 
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List of abbreviations and acronyms (in alphabetical order): 
 
IQR=Interquartile range 
LPV= Local, provoked vulvodynia 
NRS= Numerical Pain Score 
TAUH= Tampere University Hospital 
TENS= Transcutaneous Electrical Nerve Stimulation 
VD= vulvodynia 
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Figure 1. Patient flow chart (study design)
1) 
Patients who fulfilled the Friedrich's two first criteria: pain on attempted vaginal entry 
and tenderness to pressure localized in the vulvar vestibule
Review of the 
patient record, 
diagnosis of 
Vulvodynia +/-
(n=133)1
Patient 
identification with 
ICD-code from the 
hospital records 
(n=343)
Questionnaires sent 
(n=133)
September 2014
Questionnaires
returned (n=70)
November 2014
Figure 2. Vulvodynia treatment protocol in Tampere University Hospital 
1
2nd visit
 3 3rd visit1st visit to a physician 
2
3-6 months
No response
No response
4)
 Local injections and topical neuromodulation are given 1-3 times in every 3-4 weeks. Laser therapy has mostly been replaced by other 
treatment modalities.
6-18 months
1)
 Vulvodynia treatment protocol has been in clinical use since 2009. For every patient, treatment of VD is individualized and different 
treatment protocols may be used in varying combinations.
2)
 Patient is also given verbal and written information about VD, instructions for personal hygiene (e.g. avoiding tight clothing, washing 
with soap), stopping hormonal contraception if considered adequate. After the first visit patient is referred to physiotherapy and/or 
sexual counseling. Medical therapy and other therapies may overlap and be given at the same time.
3)
 Patient is encouraged to continue physiotherapy and/or sexual counseling if considered beneficial in terms of pain reduction
No responseLocal
Generalized
No response
VD diagnosis, 
symptoms: 
local/generalized
TCA or pregabalin 
for minimum of 3-4 
months
Topical gabapentin 
6% for 6-8 weeks 
and/or desenzitizing
gel (lidocain) before 
intercourse
Local injections or 
topical 
neuromodulation to 
the painful site 4
Change of 
medication: another 
antidepressant/anti-
convulsant
Evaluate for surgery 
(posterior 
vestibulectomy)
Evaluate for sacral 
neuromodulation
Table 1. Content of the questionnaire sent to vulvodynia patients identified from the hospital record
Backround Information
Age
Nulliparous/Number of births
Symptoms before/after giving birth
Recurrent yeast infections yes/no, diagnosed by a physician yes/no
Symptoms before/after yeast infections
Bacterial vaginosis yes/no, diagnosed by a physiscian yes/no
Symptoms before/after bacterial vaginosis
Hormonal contraception yes/no, name of the contraceptives used
Other medications (name of the medication)
Beginning of symptoms, at which age
Delay between first symptoms and treatment
First contact about the symptoms (e.g. Public health center/private doctor)
Unit that referred patient to University Hospital (e.g. Public health center/Private)?
Name all treatment modalities you received for vulvodynia (examples given)
Vulvodynia symptoms
Are the symptoms local/generalized?
Provoked/not
Pain (NRS scale, 0= no pain, 10= worst pain imaginable)
Pain before treatments
Pain after treatments
Patient satisfaction (5-point scale, 0=Not satisfied at all, 5=Very satisfied)
Referral to University hospital, on time
Treatment protocol satisfaction
Information given about vulvodynia verbal/written
Satisfaction to the physician
Satisfaction to the sexual counselling by a trained nurse
Satisfaction to the physiotherapist
Efficacy of different treatments received
Quality of life
Partner satisfaction
Relationship satisfaction after treatments
Table 2. Characteristics of the Study Population (n=70)
Age, median (interquartile range) 30 (25-41)
Onset of symptoms (years), median (interquartile range) 20 (17.25-27.50)
Duration of symptoms before treatments (years), median (interquartile range)1.0 (0.5-4.75)
Dyspareunia n(%) missing information=1 64 (91.4 )
Nulliparous, n (%), missing information n=2 54 (77.1)
Postmenopausal n (%) 12 (17.1)
Local pain, n (%) 56 (80)
Generalized pain, n (%) 14 (20)
Psychiatric disorder
1
, past or current, n (%) 20 (28.6)
1)
 Depression or bipolar disorder
Table 3. Different treatment modalities used for vulvodynia patients
n %
Desenzitizing gel 
1)
58 82,9
Physiotherapy (biofeedback, TENS) 55 78,6
Sexual counseling by a trained nurse 52 74,3
Topical gabapentin 6% 38 54,3
Topical neuromodulation 
2)
23 32,9
Local injections to painful site
 3)
18 25,7
TCA 
4)
14 20,0
Surgery 
5)
13 18,6
Pregabalin 150-300 mg 10 14,3
Laser treatment 3 4,3
Sacral neuromodulation 2 2,9
4) 
Tri-cyclic antidepressant, amitriptyline 10-40 mg most commonly used
5) 
Modified posterior vestibulectomy, surgical removal of painful area
1)
 Lidocain gel to the painful area in vulva 30 minutes before intercourse. 
2)
 Podophyllotoxin (5 mg/mL Wartec®) applied locally to tender points of vestibulum following 5% acetic 
3)
 2-4 ml of cortisone (betamethasone) and long acting anaesthetic agent (bupivacaine), both 50% and 50 %, 
injected submucuously to the painful site. 
Treatment
Number of 
patients
NRS score before 
treatment, median 
(IQR)
NRS score after 
treatment, median 
(IQR)
P-value 
1)
Desenzitizing gel (lidocain)
Yes 58 8 (8-9) 4 (2-7)
No 12 9 (8-10) 3 (2-7)
Physiotherapy
Yes 55 9 (8-9) 4 (2-7)
No 15 8 (8-9) 3.5 (1-6.25)
Sexual counseling by a trained nurse
Yes 52 8 (8-9) 4 (2-7)
No 18 8 (8-9) 4 (2-7)
Topical gabapentin 6%
Yes 38 8 (8-9) 5 (3-7)
No 32 9 (8-9.75) 3 (1.25-7)
Topical neuromodulation
Yes 23 9 (8-9) 6 (3-7)
No 47 8 (8-9) 4 (2-7)
Local injections to the painful site
Yes 18 8 (8-9) 4.5 (2.75-8)
No 52 8 (8-9) 4 (2-7)
TCA 
Yes 17 9 (8-9) 5 (2.5-7.5)
No 53 8 (8-9) 4 (2-7)
Surgery 
Yes 13 8 (8-9) 3 (1.5-8)
No 57 8 (8-9) 4 (2-7)
Pregabalin
Yes 10 8.5 (8.0-9.25) 3 (2-7.50)
No 60 8 (8-9) 4 (2-7)
Laser treatment
Yes 3 8 (7,8,9 )
2
4 (2,4,6)
2
No 67 8 (8-9) 4 (2-7)
Sacral neuromodulation
Yes 2 9 (8,10)
3
5 (3,7)
3
No 68 8 (8-9) 4 (2-7)
1)
 P-value based on NRS score reduction before and after treatments of treated and not treated patients
2) 
All NRS numbers reported, not interquartile range
3 
All NRS numbers reported, not interquartile range
Table 4. Different treatment modalities and self reported pain on NRS score before and after treatment
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
